Compare NBY & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBY | CION |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 464.0M |
| IPO Year | 2007 | 2011 |
| Metric | NBY | CION |
|---|---|---|
| Price | $1.47 | $8.05 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.3M | 481.7K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | ★ 15.04% |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | ★ $1.86 | $17.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $7.97 |
| 52 Week High | $19.95 | $12.57 |
| Indicator | NBY | CION |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 26.68 |
| Support Level | $0.94 | N/A |
| Resistance Level | $2.66 | $9.50 |
| Average True Range (ATR) | 0.24 | 0.24 |
| MACD | 0.30 | -0.04 |
| Stochastic Oscillator | 43.78 | 25.84 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.